Abstract
Inflammatory neuropathies are treatable immune-mediated disorders of the peripheral nerves, the prevalence of which is higher than previously believed. Although there are now established treatments of proven benefit for acute and chronic inflammatory neuropathies consisting of intravenous immunoglobulins, corticosteroids and plasma exchanges, there are patients who fail to respond to these therapies. Immunosuppressants have been used in these refractory patients and also to lower the requirements of therapies of established efficacy due to their cost (e.g. immunoglobulins) or sideeffects (e.g., corticosteroids). These drugs include “conventional” immunosuppressants like azathioprine, cyclophosphamide etc. and also newer drugs like Rituximab. Other immunomodulatory drugs like interferon beta have also been trialled in some patients. Currently the role of newer drugs like Fingolimod in inflammatory neuropathies is being studied. In this article, the issue of treating inflammatory neuropathies with immunomodulatory and immunosuppressive agents in the context of their potential adverse effects, is reviewed and discussed. The published evidence on these drugs is reviewed, rationale behind the use of such drugs is analyzed and benefit to risk ratio highlighted.
Keywords: Immunomodulation, immunosuppression, inflammatory neuropathy.
Current Drug Safety
Title:Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Volume: 8 Issue: 4
Author(s): Saiju Jacob and Yusuf A. Rajabally
Affiliation:
Keywords: Immunomodulation, immunosuppression, inflammatory neuropathy.
Abstract: Inflammatory neuropathies are treatable immune-mediated disorders of the peripheral nerves, the prevalence of which is higher than previously believed. Although there are now established treatments of proven benefit for acute and chronic inflammatory neuropathies consisting of intravenous immunoglobulins, corticosteroids and plasma exchanges, there are patients who fail to respond to these therapies. Immunosuppressants have been used in these refractory patients and also to lower the requirements of therapies of established efficacy due to their cost (e.g. immunoglobulins) or sideeffects (e.g., corticosteroids). These drugs include “conventional” immunosuppressants like azathioprine, cyclophosphamide etc. and also newer drugs like Rituximab. Other immunomodulatory drugs like interferon beta have also been trialled in some patients. Currently the role of newer drugs like Fingolimod in inflammatory neuropathies is being studied. In this article, the issue of treating inflammatory neuropathies with immunomodulatory and immunosuppressive agents in the context of their potential adverse effects, is reviewed and discussed. The published evidence on these drugs is reviewed, rationale behind the use of such drugs is analyzed and benefit to risk ratio highlighted.
Export Options
About this article
Cite this article as:
Jacob Saiju and Rajabally A. Yusuf, Immunomodulation in Inflammatory Neuropathies: Rationale and Safety, Current Drug Safety 2013; 8 (4) . https://dx.doi.org/10.2174/15748863113089990040
DOI https://dx.doi.org/10.2174/15748863113089990040 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology Phytotherapeutic and Natural Compound Applications for Age-Related, Inflammatory and Serious Eye Ailments
Current Molecular Pharmacology Job Stress and Blood Pressure: A Critical Appraisal of Reported Studies
Current Hypertension Reviews Polyphenols: Well Beyond The Antioxidant Capacity: Polyphenol Supplementation and Exercise-Induced Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Davunetide: Peptide Therapeutic in Neurological Disorders
Current Medicinal Chemistry Sleep and Circadian Profiles of Bipolar Disorder: From Chronobiology to Novel Therapeutic Strategies
Current Psychiatry Reviews The Efficacy of Conceptual DFT Descriptors and Docking Scores on the QSAR Models of HIV Protease Inhibitors
Medicinal Chemistry The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly
Current Drug Safety Periostin as a Heterofunctional Regulator of Cardiac Development and Disease
Current Genomics PI3K-Akt Signaling and Viral Infection
Recent Patents on Biotechnology Advances in HIV-1 Entry Inhibitors: Strategies to Interfere with Receptor and CoReceptor Engagement
Current Pharmaceutical Design G Protein-Coupled Receptors – Potential Roles in Clinical Pharmacology
Cardiovascular & Hematological Agents in Medicinal Chemistry QSAR Studies on HIV-1 Protease Inhibitors Using Non-Linearly Transformed Descriptors
Current Computer-Aided Drug Design P2Y Receptors in the Mammalian Nervous System: Pharmacology, Ligands and Therapeutic Potential
CNS & Neurological Disorders - Drug Targets Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Infectious Disorders - Drug Targets They Must Hold Tight: Junction Proteins, Microbiota And Immunity In Intestinal Mucosa
Current Protein & Peptide Science Vinyl Sulfone Containing Parasitic Cysteinyl Protease Inhibitors
Current Bioactive Compounds Alterations in Glucose Metabolism on Cognition: A Possible Link Between Diabetes and Dementia
Current Pharmaceutical Design Fc Engineering to Improve the Function of Therapeutic Antibodies
Current Pharmaceutical Biotechnology Celiac Disease: Pathogenesis and Novel Therapeutic Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets